Eupraxia Pharmaceuticals Inc. EPRX
Pharmaceuticals and Biotechnology · data as of November 13, 2026
Eupraxia Pharmaceuticals Inc. (EPRX) is a healthcare company listed in the US with a market value of about $537M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals is listed in the US and classified in pharmaceuticals and biotechnology. It was profitable in 0 of the last 4 years in our data.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 4 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | — |
| Net income | -$39M | -$26M | -$28M | -$18M |
| Free cash flow | -$29M | -$30M | -$21M | -$14M |
| EPS (diluted) | $-0.59 | $-0.39 | $-0.43 | $-0.28 |
| Net margin | — | — | — | — |
| ROIC | — | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 12 analysts is $16.71, 105% above the current price; targets range from $14.00 to $25.00; the consensus rating is “Strong buy”; expected EPS is $-0.96 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Eupraxia Pharmaceuticals pay a dividend?
Not currently.
Is Eupraxia Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Eupraxia Pharmaceuticals scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.